AB&B Bio-Tech shares on Hong Kong Stock Exchange suspended pending delayed annual results

Reuters04-01
AB&B Bio-Tech shares on Hong Kong Stock Exchange suspended pending delayed annual results
  • Trading in AB&B Bio-Tech shares (2627) on Hong Kong Stock Exchange will be suspended from 9:00 a.m. on April 1, 2026.
  • Hong Kong Stock Exchange triggered the halt under Listing Rules requirement tied to delayed publication of fiscal 2025 annual results.
  • Audit remains incomplete due to ongoing review of certain fund investments plus consultancy payments.
  • Board meeting slated for March 31 to consider annual results release was postponed to a date to be announced.
  • Trading will remain halted until AB&B Bio-Tech publishes its fiscal 2025 annual results.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260401-12084514), on April 01, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment